Skip to main content
. 2022 Jun 24;14(7):1335. doi: 10.3390/pharmaceutics14071335

Figure 1.

Figure 1

Binding and agonist activity of TrkB antibody and TXB4—TrkB fusions. (A) Diagram of various antibody formats with the TXB4 VNAR module represented by black-filled circles. The binding of TXB4-TrkB antibody fusion to mTfR1 and (B) hTfR1. (C) was measured by ELISA compared to the unmodified TXB4 VNAR-hFc and TXB4 module as references. (D) Binding to TrkB was measured by ELISA compared to the unmodified TXB4 VNAR-hFc and TXB4 as references compared to the same as references. OD values were used for 4-parametric non-linear regression model to calculate EC50s (±SD, n = 3). (E) TrkB and TXB4-TrkB fusion protein were tested for agonist activity using the TrkB-NFAT-bla CHO-K1 reporter cell line assay. Data were normalized and 4-parametric non-linear regression model was used to calculate EC50 values (±SD, n = 3–5) (see Table 2).